Delaware chronic-pain Treatment Agreements, documented from the statewide rule outward
Status: Delaware evidence build reviewed through October 5, 2026. This library separates the statewide chronic-pain signed-agreement mandate, mandatory monitoring, optional agreement clauses, professional-board rules, pain-care safeguards, education requirements, rulemaking history, and formal change path.
Use this Delaware record
| What is required | Delaware’s Uniform Controlled Substances Act Regulations require a signed Treatment Agreement for covered chronic-pain patients and separate six-month PMP and fluid-screen monitoring. |
|---|---|
| Who it applies to | Covered chronic-pain patients and practitioners under the statewide controlled-substances regulation; many individual agreement clauses remain discretionary. |
| Who can change it | The Delaware Department of State and the responsible controlled-substances regulatory bodies control the regulation through formal rulemaking. |
| What to do next | See the rulemaking route or submit a Delaware agreement. |
Current statewide legal baseline
Delaware’s Uniform Controlled Substances Act Regulations require a covered chronic-pain practitioner to obtain a signed Treatment Agreement. Chronic pain is defined for the regulation as continuous or nearly continuous pain lasting more than three months.
| Requirement | Current Delaware regulation |
|---|---|
| Signed Treatment Agreement | Required for covered chronic-pain patients. |
| PMP review | At least every six months, more often when clinically indicated, and when benzodiazepines or risk signals are present. |
| Fluid drug screening | At least once every six months. |
| Risk assessment | Required. |
| Alternative-treatment history | Must be documented, including non-pharmacological options. |
| Medical-record agreement | Written, signed by practitioner and patient/proxy, and retained in the medical record. |
Delaware state-level records
- Delaware Chronic-Pain Signed Treatment Agreement Requirement
- Delaware PMP, Drug Testing, and Risk Assessment Record
- Delaware Treatment Agreement Terms and Practice-Policy Boundary
- Delaware Prescriber Scope and Exemptions Record
- Delaware Board of Medical Licensure High-Risk Agreement Rule
- Delaware Individualized Pain-Care and Undertreatment Safeguards
- Delaware Controlled-Substance Education and Registration Record
- Delaware 2016-2017 Opioid Rulemaking Origin Record
- Delaware Contract-for-Care Authority and Rulemaking Record
The agreement is mandatory; many individual clauses are not
Delaware requires the signed agreement itself. The regulation then lists several clauses that the agreement may include at the practitioner’s discretion, such as lost-prescription protocols, early-refill rules, one-practitioner sourcing, restrictions on unauthorized substances, and specified consequences for violation. Those should not be misrepresented as identical mandatory language in every Delaware agreement.
Monitoring requirements are independently mandatory
Even though some monitoring language appears in the list of discretionary agreement clauses, Section 9.8 independently requires PMP review at least every six months and fluid drug screening at least every six months for covered chronic-pain patients.
Professional Board layer
The Board of Medical Licensure and Discipline separately requires a written agreement for high-risk or substance-use-history patients under its Section 18 pain-management standard. That agreement must address requested screening, refill frequency, discontinuation criteria, and one-practitioner/one-pharmacy sourcing where possible.
Scope and exemptions
The statewide Section 9 rule covers physicians, dentists, podiatrists, nurse practitioners, physician assistants, and other authorized controlled-substance prescribers, excluding veterinarians from this definition. Hospice, active cancer treatment, cancer-related pain, terminal/palliative care, and qualifying hospital treatment are exempt.
Individualized pain-care safeguards
Delaware’s Medical Board simultaneously states that appropriate pain relief is part of quality medical practice, inappropriate undertreatment may itself be a standards problem, practitioners should not fear discipline for legitimate controlled-substance treatment, and treatment should not be judged solely by medication quantity or duration.
Education and registration
Delaware controlled-substance registrants complete state-approved training on safe prescribing and pain treatment and attest to recurring continuing education related to controlled substances or chronic pain.
Rulemaking origin
The modern statewide agreement and monitoring system emerged from Controlled Substance Advisory Committee rulemaking in 2015-2017. The chronic-pain signed-agreement requirement remains in the current regulation.
Formal change route
16 Del. C. §4731 gives the Secretary of State authority to promulgate controlled-substance rules and establishes the Controlled Substance Advisory Committee. Current Secretary of State Charuni Patibanda-Sanchez holds the statutory regulatory office; current Committee President Joseph M. Parise, D.O. leads the advisory body. Under 29 Del. C. §10114, any person may petition the agency to amend or repeal a regulation, with action at the next regular meeting unless the petition arrives within five days.
Submit a missing Delaware agreement
Submit a Delaware Contract for Care
Primary Delaware authorities
- Uniform Controlled Substances Act Regulations — Section 9
- Board of Medical Licensure and Discipline — Section 18
- 16 Del. C. §4731
- 29 Del. C. §§10114-10115
Reviewed: October 5, 2026.
Evidence boundary: Delaware’s signed Treatment Agreement is a binding statewide regulatory requirement for covered chronic-pain treatment. Optional agreement clauses, the separate Medical Board high-risk rule, clinic-created policies, and exempt patient categories remain distinct evidence layers.